{"id":3832,"date":"2021-03-05T11:29:05","date_gmt":"2021-03-05T16:29:05","guid":{"rendered":"https:\/\/www.wmfc.ca\/?page_id=3832"},"modified":"2024-03-01T17:24:34","modified_gmt":"2024-03-01T22:24:34","slug":"test-page-3","status":"publish","type":"page","link":"https:\/\/www.wmfc.ca\/fr\/tst-page-3\/","title":{"rendered":"Tst Page - 3"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"--awb-bg-size:cover;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-1\"><h2><strong>To Anyone who lands here: <\/strong><\/h2>\n<p>This is a TEST page.<\/p>\n<p>That means what you see here may not work.\u00a0 It may not work as you expect.\u00a0 Your mileage may vary!!!<\/p>\n<p>Basically, keep your mouse off it unless you&#8217;ve been specifically invited &#8212; and even then, well, I may have just changed things.<\/p>\n<p>And you know who &#8220;I&#8221; is.\u00a0 Get in touch.<\/p>\n<\/div><ul style=\"--awb-iconcolor:#717171;--awb-line-height:23.8px;--awb-icon-width:23.8px;--awb-icon-height:23.8px;--awb-icon-margin:9.8px;--awb-content-margin:33.6px;\" class=\"fusion-checklist fusion-checklist-1 fusion-checklist-default type-icons\">\n<li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-no\"><i class=\"fusion-li-icon fa fa-phone\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">xxx yyy-zzzz<\/div><\/li>\n<\/ul><div class=\"fusion-text fusion-text-2\"><p>Re-subscribe a mailchimp user.\u00a0 Info from <a href=\"https:\/\/mailchimp.com\/help\/add-a-signup-form-to-your-website\/\" target=\"_blank\" rel=\"noopener\">https:\/\/mailchimp.com\/help\/add-a-signup-form-to-your-website\/<\/a>, and then the embedded code from SignupForms in Audience tab of MailChimp.<\/p>\n<\/div><!-- Begin Mailchimp Signup Form -->\n<link href=\"\/\/cdn-images.mailchimp.com\/embedcode\/classic-10_7.css\" rel=\"stylesheet\" type=\"text\/css\">\n<style type=\"text\/css\">\n\t#mc_embed_signup{background:#fff; clear:left; font:14px Helvetica,Arial,sans-serif; }\n\t\/* Add your own Mailchimp form style overrides in your site stylesheet or in this style block.\n\t   We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. *\/\n<\/style>\n<div id=\"mc_embed_signup\">\n<form action=\"https:\/\/wmfc.us4.list-manage.com\/subscribe\/post?u=95d96f3ddf126a405ea7e8a68&id=6cae47c1a4\" method=\"post\" id=\"mc-embedded-subscribe-form\" name=\"mc-embedded-subscribe-form\" class=\"validate\" target=\"_blank\" novalidate>\n    <div id=\"mc_embed_signup_scroll\">\n\t<h2>Subscribe<\/h2>\n<div class=\"indicates-required\"><span class=\"asterisk\">*<\/span> indicates required<\/div>\n<div class=\"mc-field-group\">\n\t<label for=\"mce-EMAIL\">Email Address  <span class=\"asterisk\">*<\/span>\n<\/label>\n\t<input type=\"email\" value=\"\" name=\"EMAIL\" class=\"required email\" id=\"mce-EMAIL\">\n<\/div>\n\t<div id=\"mce-responses\" class=\"clear\">\n\t\t<div class=\"response\" id=\"mce-error-response\" style=\"display:none\"><\/div>\n\t\t<div class=\"response\" id=\"mce-success-response\" style=\"display:none\"><\/div>\n\t<\/div>    <!-- real people should not fill this in and expect good things - do not remove this or risk form bot signups-->\n    <div style=\"position: absolute; left: -5000px;\" aria-hidden=\"true\"><input type=\"text\" name=\"b_95d96f3ddf126a405ea7e8a68_6cae47c1a4\" tabindex=\"-1\" value=\"\"><\/div>\n    <div class=\"clear\"><input type=\"submit\" value=\"Subscribe\" name=\"subscribe\" id=\"mc-embedded-subscribe\" class=\"button\"><\/div>\n    <\/div>\n<\/form>\n<\/div>\n<script type='text\/javascript' src='\/\/s3.amazonaws.com\/downloads.mailchimp.com\/js\/mc-validate.js'><\/script><script type='text\/javascript'>(function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';fnames[1]='FNAME';ftypes[1]='text';fnames[2]='LNAME';ftypes[2]='text';fnames[3]='ADDRESS';ftypes[3]='address';fnames[4]='PHONE';ftypes[4]='phone';fnames[5]='BIRTHDAY';ftypes[5]='birthday';}(jQuery));var $mcj = jQuery.noConflict(true);<\/script>\n<!--End mc_embed_signup--><div class=\"fusion-tabs fusion-tabs-1 classic vertical-tabs icon-position-left mobile-mode-accordion\" style=\"--awb-title-border-radius-top-left:10%;--awb-title-border-radius-top-right:10%;--awb-title-border-radius-bottom-right:10%;--awb-title-border-radius-bottom-left:10%;--awb-alignment:start;--awb-inactive-color:#ce0000;--awb-background-color:#ffffff;--awb-border-color:#000000;--awb-active-border-color:#325c94;\"><div class=\"nav\"><ul class=\"nav-tabs\" role=\"tablist\"><li class=\"active\" role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-73f1473460d7b3c9367\" aria-selected=\"true\" id=\"fusion-tab-overview\" href=\"#tab-73f1473460d7b3c9367\"><h4 class=\"fusion-tab-heading\">Overview<\/h4><\/a><\/li><li role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-561fbd06bf8a303fce9\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-booklet\" href=\"#tab-561fbd06bf8a303fce9\"><h4 class=\"fusion-tab-heading\">Booklet<\/h4><\/a><\/li><li role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-7520ec94cda0c60b9d5\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-aboutbtkinhibitors\" href=\"#tab-7520ec94cda0c60b9d5\"><h4 class=\"fusion-tab-heading\">About BTK Inhibitors<\/h4><\/a><\/li><li role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-6a71f5627342f691b3b\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-car-ttherapies\" href=\"#tab-6a71f5627342f691b3b\"><h4 class=\"fusion-tab-heading\">CAR-T therapies<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs\" role=\"tablist\"><li class=\"active\" role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-73f1473460d7b3c9367\" aria-selected=\"true\" id=\"mobile-fusion-tab-overview\" href=\"#tab-73f1473460d7b3c9367\"><h4 class=\"fusion-tab-heading\">Overview<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-overview\" id=\"tab-73f1473460d7b3c9367\">\n<p>There are many different treatment options available for WM patients, and their numbers are increasing as researchers discover more about the biology and genetics of the disease.<\/p>\n<p>Treatment may consist of just one drug (single-agent therapy), or two or more drugs (combination therapy).\u00a0 Most studies seem to indicate that combination therapies are more effective, resulting in better and\/or longer-lasting responses.<\/p>\n<p>Treatment can usually be administered in an outpatient setting or at home.\u00a0 It may be oral, by intramuscular or subcutaneous injection, or by intravenous therapy.\u00a0 Some treatments require that certain medications be taken the day before or the day of treatment in order to minimize associated side effects.<\/p>\n<p>Treatment cycles may take several weeks to months, depending on the course of therapy chosen. It is not unusual to have a round of therapy and then wait a week or a month before another round of treatment, although some of the newer oral therapies require daily dosing instead on an on-going\/steady state basis. Hematologist-oncologists follow established protocols for treatment but may make adjustments depending on side effects or response to therapy.<\/p>\n<p>Most of the treatments in use today were originally approved for the related cancers of follicular lymphoma, chronic lymphocytic leukemia, and multiple myeloma.\u00a0 Once additional Phase 1 and Phase 2 clinical trials established that these treatments had both an acceptable safety profile and were effective <em>for WM patients as well<\/em>, they were prescribed for \u201coff label\u201d use in WM.<\/p>\n<p>The standard first-line treatment protocol (i.e., the typical first treatment for a WM patient) in Canada, across all provinces, is currently Bendamustine plus Rituximab.\u00a0 But all WMers are unique and different.\u00a0 Your oncologist may recommend other approaches, based on your individual symptoms and circumstances.\u00a0 Below, we provide:<\/p>\n<ul>\n<li>an overview of the breadth of treatments available today for WM,<\/li>\n<li>a few words about the class of drugs known as BTK inhibitors, and their status in Canada, and<\/li>\n<li>a pointer to information about CAR-T therapies.<\/li>\n<\/ul>\n<p>More information can be obtained by visiting the various subsections in <a href=\"\/education\/\">Education<\/a> on our website.<\/p>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs\" role=\"tablist\"><li role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-561fbd06bf8a303fce9\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-booklet\" href=\"#tab-561fbd06bf8a303fce9\"><h4 class=\"fusion-tab-heading\">Booklet<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-booklet\" id=\"tab-561fbd06bf8a303fce9\">\n<p><strong>Download your own copy<\/strong> of a booklet entitled <a href=\"https:\/\/drive.google.com\/file\/d\/1oBo-e-o9dg-pZH1uQ5I-Nv3zPiQdF3Sw\/view?usp=drive_link\" target=\"_blank\" rel=\"noopener\">Essential Information: A Physician&#8217;s Guide<\/a>.\u00a0 In partnership with the IWMF, this booklet is part of a global initiative to educate patients and doctors, worldwide.\u00a0 It is a compilation of current knowledge on the diagnosis, treatment and established protocols for WM, intended as a guide to physicians.\u00a0 Although more medically written, we feel it is critical for all patients to be aware of and understand their own treatment options.\u00a0 Its authors are two WM specialist MDs from the Bing Center for WM, at the Dana-Farber Cancer Institute.<\/p>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs\" role=\"tablist\"><li role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-7520ec94cda0c60b9d5\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-aboutbtkinhibitors\" href=\"#tab-7520ec94cda0c60b9d5\"><h4 class=\"fusion-tab-heading\">About BTK Inhibitors<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-aboutbtkinhibitors\" id=\"tab-7520ec94cda0c60b9d5\">\n<p>BTK inhibitors are daily <u>oral<\/u> drugs that target the Bruton\u2019s tyrosine kinase (BTK) pathway in B-cell growth and development.<\/p>\n<p>With the exception of Bendamustine + Rituximab (BR), no other drug therapy routinely gives such long remissions.\u00a0 BTK inhibitors are typically less toxic than BR, and the newer-generation of BTK inhibitors improve on the older ones, although they have not been studied as long.\u00a0 However, BTK inhibitors are \u201cforever drugs\u201d, in that one takes them until there is disease progression or drug toxicity.\u00a0 And with that comes a much, much higher cost, whether to the medical system or to the patient.<\/p>\n<p>In the Canadian context, the following BTK inhibitors are visible:<\/p>\n<ul>\n<li>Imbruvica (ibrutinib) by Janssen.\u00a0 This was the first BTK inhibitor, and the first drug specifically designated for the treatment of WM, approved by the US FDA in 2015.\u00a0 It has since been approved by Health Canada for the treatment of WM.<\/li>\n<li>Brukinsa (zanubrutinib) by Beigene.\u00a0 This was approved in May 2021 by Health Canada for the treatment of WM.<\/li>\n<li>Calquence (acalabrutinib) by Astra Zeneca.\u00a0 This has been approved by Health Canada for CLL but is also in a WM clinical trial across Canada.\u00a0 See our coverage of <a href=\"\/2021\/06\/15\/brawm-trial\/\">the BRAWM trial<\/a>.<\/li>\n<li>Pirtobrutinib (formerly Loxo-305) by Loxo Oncology.\u00a0 This drug is in clinical trials in the US.\u00a0 It is in a new class of BTK inhibitors known as &#8220;non-covalent&#8221; BTK inhibitors.\u00a0 Importantly, it has shown that it can be effective even after patients have relapsed on Ibrutinib.\u00a0 These trials are open to suitable Canadian WM patients.\u00a0 However, costs for Canadians to participate in US clinical trials vary widely, by site.\u00a0 For more information on participating in a US trial, as a Canadian, <a href=\"\/who-we-are\/contact-us\/\">contact us<\/a>.\u00a0 Also, <a href=\"\/2021\/10\/06\/participating-in-a-us-based-trial-from-canada-during-a-pandemic\/\">see one member&#8217;s experience<\/a> in such a trial.<\/li>\n<li>Nemtabrutinib (formerly ARQ 531 and MK-1026) by Merck.\u00a0 This drug is in clinical trials in the US and in Canada (<a href=\"\/2022\/02\/23\/another-clinical-trial-available-in-canada-nemtabrutinib\/\">see our coverage<\/a>).\u00a0 It is another member of the class of non-covalent BTK inhibitors.<\/li>\n<\/ul>\n<p>The status of funding for BTK inhibitors by the provinces is mixed &#8212; at this point (mid-2023), some do and some do not.\u00a0 Provinces do have the option of granting patients Compassionate Access to these drugs under specific conditions.\u00a0 See more discussion of paying for BTK inhibitors in our list of <a href=\"\/about-wm\/common-canadian-questions-answered\/\">Common Canadian Questions<\/a>.\u00a0 The cost of the treatment should never be a barrier if it is the best option for you.<\/p>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs\" role=\"tablist\"><li role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-6a71f5627342f691b3b\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-car-ttherapies\" href=\"#tab-6a71f5627342f691b3b\"><h4 class=\"fusion-tab-heading\">CAR-T therapies<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-car-ttherapies\" id=\"tab-6a71f5627342f691b3b\">\n<p>One of the more exciting developments is CAR T-cell therapy, which is being used, successfully, on WM patients in clinical trials and is considered to be potentially curative.\u00a0 There are, however, very few of those clinical trials in Canada.<\/p>\n<p>CAR-T therapy involves taking a patient&#8217;s T cells, performing genetic engineering on them.\u00a0 That engineering gives the T cells new receptors, which allows those T cells to target a specific molecule typically present on the surface of a specific type of cancer cell.\u00a0 The new receptors are called <b>chimeric antigen receptors<\/b> (<b>CARs<\/b>) and thus (since we are dealing with T-cells), we have CAR-T therapy.\u00a0 Scientists harvest T cells from people, genetically alter them, multiply them, then infuse the resulting collection of CAR T cells into patients to attack their tumors.<\/p>\n<p>As noted above, the use of CAR-T therapy for WM is still at the clinical trial stage, and rare.\u00a0 The Princess Margaret Hospital in Toronto has developed <a href=\"https:\/\/pmcancerclasses.ca\/course\/view.php?id=44\" target=\"_blank\" rel=\"noopener\">an 8-part video course<\/a> for patients thinking about CAR-T therapy.\u00a0 If you are contemplating CAR-T, or it has been mentioned to you by your medical team, this set of videos may be of value.<\/p>\n<p>Also, see our post at <a href=\"\/2021\/08\/29\/car-t-cell-progress-in-canada\/\">CAR T-cell Progress in Canada<\/a> for more information and links about CAR-T therapies.<\/p>\n<\/div><\/div><\/div><div class=\"fusion-text fusion-text-3\"><p>This is a test of <a href=\"https:\/\/drive.google.com\/file\/d\/1-Y8W2qYI_xSTAH3FKJYf9az0XlP6wNAV\/view?usp=sharing\" target=\"_blank\" rel=\"noopener\">distant links<\/a><\/p>\n<\/div><div class=\"accordian fusion-accordian\" style=\"--awb-border-size:0px;--awb-icon-size:25px;--awb-content-font-size:17px;--awb-icon-alignment:left;--awb-hover-color:#ffffff;--awb-border-color:#e7e4e2;--awb-background-color:#ffffff;--awb-divider-color:#d60a15;--awb-divider-hover-color:#d60a15;--awb-icon-color:#365f96;--awb-title-color:#0262f2;--awb-content-color:#000000;--awb-icon-box-color:#333333;--awb-toggle-hover-accent-color:#37445b;--awb-title-font-family:&quot;Open Sans&quot;;--awb-title-font-weight:700;--awb-title-font-style:normal;--awb-title-font-size:16px;--awb-content-font-family:&quot;Open Sans&quot;;--awb-content-font-style:normal;--awb-content-font-weight:400;\"><div class=\"panel-group fusion-toggle-icon-unboxed\" id=\"accordion-3832-1\"><div class=\"fusion-panel panel-default panel-4e364ac5167e95726 fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:#0262f2;--awb-content-color:#000000;\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_4e364ac5167e95726\"><a aria-expanded=\"false\" aria-controls=\"4e364ac5167e95726\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-3832-1\" data-target=\"#4e364ac5167e95726\" href=\"#4e364ac5167e95726\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon awb-icon-plus\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">Toggle me this<\/span><\/a><\/h4><\/div><div id=\"4e364ac5167e95726\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_4e364ac5167e95726\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p>Here&#8217;s a toggle to deal with<div class=\"fusion-menu-anchor\" id=\"TestAnchor\"><\/div>\n<p>asdlkj alsdjk alskdj alskdj alskdj<\/p>\n<p>weoiu ewioru weoriu weoiru weoiru<\/p>\n<p>xc,vmn xcvm,n x, x,mcvn x.<\/p>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-menu-anchor\" id=\"OpenTestAnchor\"><\/div><div class=\"fusion-text fusion-text-4\"><h4>This was Paul&#8217;s 2021 walk:<\/h4>\n<p style=\"padding-left: 0px;\"><iframe style=\"border: 0;\" src=\"https:\/\/esrica-atlantic.maps.arcgis.com\/apps\/dashboards\/48af580771ba4865b4f300a8bd9f1dd0\" width=\"320\" height=\"900\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>Many thanks to <a href=\"https:\/\/www.esri.ca\/en-ca\/home\" target=\"_blank\" rel=\"noopener\">ESRI Canada<\/a> for supplying this dashboard so we can track Paul&#8217;s progress!<br \/>\nThe size selections were: width=&#8221;320&#8243; height=&#8221;900&#8243;, width=&#8221;700&#8243; height=&#8221;800&#8243; and width=&#8221;1200&#8243; height=&#8221;800&#8243;<\/p>\n<\/div><script type='module' src='https:\/\/interfaces.zapier.com\/assets\/web-components\/zapier-interfaces\/zapier-interfaces.esm.js'><\/script>\n<zapier-interfaces-page-embed page-id='clm9576nj76920rlaeps4qzj4' no-background='false' style='max-width: 900px; height: 500px;'><\/zapier-interfaces-page-embed><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-background-position:left top;--awb-border-sizes-top:0px;--awb-border-sizes-bottom:0px;--awb-border-sizes-left:0px;--awb-border-sizes-right:0px;--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:0px;--awb-padding-right:5%;--awb-padding-bottom:0px;--awb-padding-left:5%;--awb-margin-top:0px;--awb-margin-bottom:0px;--awb-background-color:#333c4e;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last fusion-column-no-min-height\" style=\"--awb-padding-top:0px;--awb-padding-right:0px;--awb-padding-bottom:0px;--awb-padding-left:0px;--awb-bg-size:cover;--awb-margin-top:0px;--awb-margin-bottom:3%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-5\"><h3 style=\"text-align: center; font-size: 30px; color: #ffffff;\">Join the WMFC and stay in the loop!<\/h3>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:-25px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-text fusion-text-6 white-text\"><p style=\"text-align: center; font-size: 20px;\">Get the latest news, events and membership information via email.<\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:15px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-aligncenter\"><a class=\"fusion-button button-flat button-large button-default fusion-button-default button-1 fusion-button-span-no fusion-button-default-type\" target=\"_self\" href=\"\/membership\/\"><span class=\"fusion-button-text awb-button__text awb-button__text--default\">Join WMFC<\/span><\/a><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"class_list":["post-3832","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/pages\/3832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/comments?post=3832"}],"version-history":[{"count":8,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/pages\/3832\/revisions"}],"predecessor-version":[{"id":3849,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/pages\/3832\/revisions\/3849"}],"wp:attachment":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/media?parent=3832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}